Previewing the American Society of Clinical Oncology Annual Meeting (ASCO)
Main Stock Tickers: ABBI, ADH, AMGN, ARIA, BSM, CELG, CEGE, EXEL, DNA, GHDX, GNTA, GSK, HNAB, INGN, MLNM, MYGN, OSIP, PFE, PCYC, SUPG
This Friday will be the launch of the largest cancer and oncology event of the year. The American Society of Clinical Oncology (known as "ASCO" and referred to as ASCO hereafter) annual meeting in Atlanta, Georgia begins on Friday, June 2, 2006 and will go through Tuesday, June 6, 2006.
This is a compiled list of public companies that trade on US exchanges only, as we are geared toward the investment community perspective to this event. It is broken down by a full list exhibitors, a list of which of the companies are in each subset to identify stock candidates ahead of media teases, it also shows recent developments in Congress, and it even has a brief explanation of which companies have either confirmed they are presenting data or that have shown up in media or research reports as presenting data.
This is a few days ahead of the event so the list will only grow with many more companies confirming they intend to present embargoed data at the conference. There are some companies that have been noted recently as already having presented data, but this is discussed in each case.
For several years ASCO has been THE launch platform of choice for many biotech and drug companies to issue embargoed trial and test data to the oncology and investment community. The focus this year seems to be more on combination treatments than on new novel treatments, but in all honesty that can change literally in a matter of three seconds after new potential ground breaking data is presented.
You can peruse the ASCO website (link) to determine additional data. Because of the volume of the data ahead this is a partial document and should be considered work in progress due to the fact that it is certain to expand every few hours.
FULL LIST OF ASCO EXHIBITORS:
Under the full list of exhibitors please note that any longer written explanation than the company being a subsidiary means that the company paid extra to be listed as a Featured Exhibitor on the ASCO Annual Meeting site. The featured exhibitors are listed first and each letter of the alphabet has a space in between letters. This is only a list of the public companies, and there are likely other public company subsidiaries that were either overlooked or that were omitted intentionally. Some of the tickers may also have changed or no longer appear because of the ongoing list of mergers that are present in the medical, drug, and biotech fields.
ABAXIS...division of Abraxis Bioscience, Inc. (ABBI-NASDAQ): Developing innovative, next generation cancer therapies. Through research, innovative science, and creative thinking, we are working to redefine the treatment of cancer as we know it. As it became clear to us that nanotechnology (the science of molecular particles, measured in nanometers—billionths of a meter) would intersect with cellular biology, molecular biology, and medicine, we made the bold commitment to make this convergence happen. We have transformed the highly promising concept of protein-bound particle chemotherapeutics into an exciting new patient reality.
ANTIGENICS INC. (AGEN-NASDAQ): developing Oncophage, an autologous cancer vaccine in late-stage development for metastatic melanoma and RCC. The company's oncology portfolio also includes Aroplatin and AG-858.
ABBOTT (ABT-NYSE)
ADHEREX TECHNOLOGIES INC. (ADH-AMEX)
AETERNA ZENTARIS (AEZS-NASDAQ)
ALLOS THERAPEUTICS, INC. (ALTH-NASDAQ)
AMGEN (AMGN-NASDAQ)
ARIAD PHARMACEUTICALS INC. (ARIA-NASDAQ)
ASTRAZENECA (AZN-NYSE/ADR)
AXCAN PHARMA (AXCA-NASDAQ)
BAYER PHARMACEUTICALS CORPORATION (BAY-NYSE/ADR): discover and manufacture innovative products that will improve human and animal health worldwide by diagnosing, preventing and treating disease.
BAXTER DEUTSCHLAND GMBH, part of Baxter Labs (BAX-NYSE)
BERLEX, part of Schering AG (SHR-NYSE/ADR)
BIO-IMAGING TECHNOLOGIES, INC. (BITI-NASDAQ)
BIOGEN IDEC (BIIB-NASDAQ)
BRISTOL-MYERS SQUIBB (BMY-NYSE)
BSD MEDICAL (BSM-AMEX)
CELGENE CORPORATION (CELG-NASDAQ): innovative therapies enable providers to offer the highest-quality care for better health care outcomes, creating less demand on health care resources.
CELL GENESYS, INC. (CEGE-NASDAQ)
CEPHALON ONCOLOGY (CEPH-NASDAQ)
CEPHEID (CPHD-NASDAQ)
CHARLES RIVER LABORATORIES (CRL-NYSE)
CHIRON, now under Novartis (NVS-NYSE/ADR)
CIPHERGEN (CIPH-NASDAQ)
CLARIENT (CLRT-NASDAQ)
COVANCE (CVD-NYSE)
CYTOGEN CORPORATION (CYTO-NASDAQ)
CYTOKINETICS (CYTK-NASDAQ)
DAKO (majority shareholder is Novo Nordisk (NVO-NYSE/ADR)...pre-IPO intends to list as public stock company: Dako’s primary business area, cell-based cancer diagnostics, is divided into Pathology and Flow Cytometry, which account for 73% and 17% of sales respectively. Added to this is 10% from other products. Dako has a global market share of 35-40% in specific tissue-based cancer tests. Dako has a market share of less than 5% in the world market for flow cytometry.
ELI LILLY & COMPANY (LLY-NYSE): In addition to delivering meaningful support programs, Lilly Oncology has a long-term commitment to advance the treatment of cancer by delivering solutions through innovative technology.
EXELIXIS INCORPORATED (EXEL-NASDAQ): Committed to making a meaningful impact on the lives of cancer patients through the development of first-in or best-in class therapies.
ENZON PHARMACEUTICALS (ENZN-NASDAQ)
FRESENIUS BIOTECH GMBH (FMS-NYSE/ADR)
GE HEALTHCARE, part of General Electric (GE-NYSE): provides transformational medical technologies to help shape a new age of patient care, enabling healthcare providers to better diagnose, treat and manage disease.
GENOMIC HEALTH, INC. (GHDX-NASDAQ): Genomic Health develops clinically validated molecular diagnostics to provide individualized information on the likelihood of disease recurrence and response to therapy for cancer patients.
GENZYME (GENZ-NASDAQ): Leading biotechs dedicated to making a major positive impact on the lives of people with serious diseases.
GENENTECH BIOONCOLOGY, Genentech (DNA-NYSE)
GENITOPE CORPORATION (GTOP-NASDAQ)
GENTA INCORPORATED (GNTA-NASDAQ)
GLAXOSMITHKLINE (GSK-NYSE/ADR)
GTX INC. (GTXI-NASDAQ)
HANA BIOSCIENCES, INC. (HNAB-NASDAQ)
IMCLONE SYSTEMS INC. (IMCL-NASDAQ): dedicated to developing breakthrough medicines in the area of oncology.
IMMUNOMEDICS, INC. (IMMU-NASDAQ): Humanized antibodies tested alone or combined with the radioisotope Yttrium-90; Anti-CD22 Epratuzumab, Anti-CD20 treat NHL and SLE; hPAM4 targets MUC1 expressing pancreatic tumors.
IMS HEALTH (RX-NYSE)
INTROGEN THERAPEUTICS (INGN-NASDAQ)
KENDLE INTERNATIONAL (KNDL-NASDAQ)
KERYX BIOPHARMACEUTICALS, INC. (KERX-NASDAQ)
KYPHON INC. (KYPH-NASDAQ)
MDS PHARMA SERVICES, part of MDS (MDZ-NYSE): manages oncology trials by utilizing renowned experts, advanced technologies, global infrastructure, exceptional drug development strategies and complete clinical capabilities.
MEDIMMUNE ONCOLOGY, INC. (MEDI-NASDAQ) focused infectious diseases, cancer, and inflammatory diseases. The company has four marketed products, including Ethyol® (amifostine).
MGI PHARMA, INC. (MOGN-NASDAQ) markets Aloxi® (palonosetron hydrochloride) Injection and Gliadel® (polifeprosan 20 with carmustine implant) Wafer in the U.S.
MERCK ONCOLOGY (MRK-NYSE)
MILLENNIUM BIOTECHNOLOGIES (MBTG-NASDAQ/OTC)
MILLENNIUM PHARMACEUTICALS INC. (MLNM-NASDAQ)
MYRIAD GENETICS (MYGN-NASDAQ)
NEOPHARM INC. (NEOL-NASDAQ)
NEORX CORPORATION (NERX-NASDAQ)
NOVACEA, INC. (NOVC-NASDAQ) (very recent IPO 5/10/06)
NOVARTIS ONCOLOGY, part of Novartis (NVS-NASDAQ/ADR)
ORTHO BIOTECH PRODUCTS LP, a unit of Johnson & Johnson (JNJ-NYSE): markets PROCRIT(R) (Epoetin alfa) used to treat anemia associated with serious medical conditions.
ONYX PHARMACEUTICALS (ONXX-NASDAQ)
OSI PHARMACEUTICALS (OSIP-NASDAQ)
OXIGENE, INC. (OXGN-NASDAQ)
PHARMANET, a merged company of SFBC (SFCC-NASDAQ)
PRA INTERNATIONAL (PRAI-NASDAQ): a clinical research organization in oncology and special expertise in CNS, respiratory and cardiovascular diseases.
PAREXEL INTERNATIONAL (PRXL-NASDAQ)
PDL BIOPHARMA, INC. (PDLI-NASDAQ)
PFIZER ONCOLOGY, part of Pfizer (PFE-NYSE)
PHARMACYCLICS (PCYC-NASDAQ)
PHARMION CORPORATION (PHRM-NASDAQ)
POINT THERAPEUTICS (POTP-NASDAQ)
PPD (PPDI-NASDAQ)
QUEST DIAGNOSTICS (DGX-NYSE)
ROCHE (RHHBY-NASDAQ/ADR/OTC): Diagnostics and drug development and commercialization in oncology and multiple other disease treatments.
SUPERGEN (SUPG-NASDAQ) dedicated to acquiring, developing, and commercializing therapies for hematologists and oncologists. We market Nipent® (pentostatin for injection), Mitomycin, and SurfaceSafe®.
SANOFI-AVENTIS (SNY-NYSE/ADR)
SAVIENT PHARMACEUTICALS, INC. (SVNT-NASDAQ)
SCHERING-PLOUGH (SGP-NYSE)
SCICLONE PHARMACEUTICALS (SCLN-NASDAQ)
SGX PHARMACEUTICALS, INC. (SGXP-NASDAQ)
SIRTEX MEDICAL, INC. (SXMDF-NASDAQ/ADR/OTC)
TELIK, INC. (TELK-NASDAQ)
THRESHOLD PHARMACEUTICALS (THLD-NASDAQ)
TRANSGENOMIC, INC. (TBIO-NASDAQ)
US ONCOLOGY (former USON-NASDAQ)
VARIAN MEDICAL SYSTEMS (VAR-NYSE): supplier of advanced medical technology and oncology information systems for the treatment of cancer and/or neurological conditions.
VALLEYLAB/TYCO HEALTHCARE, part of Tyco (TYC-NYSE)
VENTANA MEDICAL SYSTEMS (VMSI-NASDAQ)
WATSON PHARMA, INC. (WPI-NYSE)
WYETH (WYE-NYSE)
YM BIOSCIENCES, INC. (YMI-AMEX)
LISTED CATEGORIES OF EACH COMPANY PRESENTATION AT ASCO
This list is from the ASCO website and it seems very incomplete, so these should just be considered incomplete.
Antibodies:
Dako, PDL
Biomarkers:
Genomic Health, Ciphergen , Quest, Transgenomic
Biotechnology (broad-based):
Antigenics, Celgene, Exelixis, Imclone, Medimmune, MGI Pharma, PRA Int'l, Adherex, AEterna Zentaris, ARIAD, Biogen-Idec, Cell Genesys, Genta, Hana Bio, Introgen, Keryx Bio, NeoRX, Novacea, OSI Pharma, Threshold Pharma
Breast Cancer:
Dako, Genomic Health, Roche, BSD Medical, Clarient, GTX, Myriad, Pfizer, Sanofi Aventis, Schering Plough
Cancer Prevention:
GTX Inc.
Cancer Survivorship:
Ciphergen
Clinical Lab Services:
Genomic Health, Genzyme, Biomedical Systems, Clarient, Transgenomic
Clinical Research:
MDS Pharma, PRA Int'l, Charles River, PPD, Threshold
Consulting:
Bio-Imaging
Contract Research:
Charles River, Covance
Cytotoxic Chemotherapy:
AEterna Zentaris, NeoRx, Sanofi Aventis
Diagnostic Imaging and Imaging Services:
GE, Bio-Imaging, Clarient
Gastrointestinal Cancer:
Dako, Immunomedics, Roche, Myriad, Pfizer, Sanofi Aventis, Sirtex, Threshold
Genitourinary Cancer:
Cell Genesys, GTX, Novacea, Onyx Pharma
Gynecological Cancer:
AEterna Zentaris, Ciphergen, Schering Plough
Head & Neck Cancer:
Medimmune, Introgen
Health Services Research:
IMS Health
Hematologic Cancer:
Celegene, Biogen Idec, Cephalon, Enzon, Novartis, Pharmion
Human Genetics:
Myriad
Immunotherapy:
Antigenics, Biogen Idec, Cell Genesys, Schering Plough
Lab Services:
Genzyme, MDS Pharma, Covance, Quest, Transgenomic
Leukemia/Lymphoma:
Celgene, Immunomedics, SuperGen, Allos, Cephalon, Enzon, Genta, PDL, Pharmacyclics, Point Therapeutics
Lung Cancer:
Axcan, NeoRx, PDL, Pharmacyclics, Point Therapeutics
Medical Devices:
Abaxis, BSD Medical, Kyphon, Valleylab/Tyco
Medical Equipment:
GE, Varian, Abaxis
Melanoma:
Antigenics, Genta, Point Therapeutics
Metastatic Disease or Brain Metastases:
Allos, Phamrcyclics, Sirtex
Microarray:
Quest
Molecular Therapeutics:
Exelixis, Onyx Pharma, OSI Pharma
Nuclear Medicine:
Immunomedics, Sirtex
Nutritional Support:
Millennium Biotechnologies-MBTG, Savient
Pediatric Oncology:
Genzyme, Enzon
Pharmaceutical (broad-based):
Bayer, Eli Lilly, Exelixis, MGI Pharma, Ortho-JNJ, Supergen, Allos, Axcan, Bristol-Myers Squibb, GlaxoSmithkline, Keryx, Millennium Pharmaceuticals-MLNM, Novacea, Novartis, OSI Pharma, Pfizer, Pharmion, Sciclone, Solvay, Wyeth
Research Technology:
SuperGen
Supportive Care:
MGI Pharma, Roche, Cephalon, Hana Bio, Savient
Trial Management:
MDS Pharma, PRA Int'l, Varian, Charles River, Covance, PPD
COMPANIES WITH NEWS OR PRESENTATIONS EXPECTED OR ANNOUNCED AT ASCO AHEAD OF TIME:
ABAXIS, a division of Abraxis Bioscience, Inc. (ABBI-NASDAQ): expected to post nanotech convergence for cancer treatments in the future.
Adherex Technologies (ADH-AMEX): Announced that the Company has concluded the Phase Ib component of its Phase Ib/II ADH-1 trial in Europe and has begun the expanded accrual restricted to lung and ovarian cancers. The study, which is examining a weekly dosing schedule of ADH-1, will now enroll patients at the maximum studied dose of 2400 mg/m2 with N-cadherin positive non-small cell lung cancer and ovarian cancer. The Company expects to enroll approximately 20 further patients in this trial. The number of patients enrolled could be increased, depending on the level of anti-tumor activity noted. The Phase Ib data will be reported at a poster discussion presentation at the 2006 American Society of Clinical Oncology Annual meeting on Saturday, June 3, 2006 from 8 a.m.-1 p.m.
Amgen (AMGN-NASDAQ): Set to report on Denosumab, an experimental osteoporosis treatment formerly known as AMG-162, could receive accelerated approval should pending Phase II data prove positive. Phase II trials to be presented at ASCO; not confirmed since this is indicated as osteoporosis treatment but it is indicated for metastatic bone diseases.
ARIAD (ARIA-NASDAQ): Comprehensive Clinical Data on ARIAD's Novel mTOR Inhibitor, AP23573, to Be Presented at the ASCO Annual Meeting. ARIAD to Host Investor Conference Call on June 5, 2006 at 6:30 p.m. EST.
BSD Medical (BSM-AMEX): may Re-report progress in the application of hyperthermia therapy to the treatment of soft tissue sarcomas, breast cancer, ovarian cancer, cervical cancer, prostate cancer, bladder cancer, esophagus cancer, gastric cancer, pancreatic cancer, intra-peritoneal cancer and colorectal cancer. This data has been presented just last week.
Celgene (CELG-NASDAQ): expected to update Phase II data for Rivlimid in the treatment of chronic lymphocytic leukemia and updates on the Revlimid phase 2 trails in multiple myeloma at ASCO.
Cell Genesys (CEGE-NASDAQ): may re-release reports of Interim Results of CG0070 Phase 1 Trial in Bladder Cancer after 3 of 9 showed a complete response and no one had side effects and the company plans to expand trial enrollment.
Exelixis (EXEL-NASDAQ): was notified by participating clinical investigators that abstracts containing data from the company's Phase I clinical trials of XL647, XL880 and XL999 have been accepted for ASCO. Data from the Phase I trials of XL647 and XL880 will be presented and discussed in the Developmental Therapeutics: Molecular Therapeutics session at 12:00 p.m. ET on Saturday, June 3rd and data from the weekly dosing arm of the Phase I XL999 trial will be published in abstract form.
Genetech (DNA-NYSE): Phase II for OSIP's Tarceva plus DNA's Avastin data will be presented. Genentech-DNA has recently received an indication for Avastin in metastatic breast cancer according to reports.
Genomic Health (GHDX-NASDAQ): reportedly will be presenting beneficial data of its Oncotype DX that will be used in a large scale study that was just initiated by the National Cancer Institute in approximately 10,000 patients and 900 centers.
Genta Inc. (GNTA-NASDAQ): announced that several abstracts related to Genasense® (oblimersen sodium) Injection, the Company's lead anticancer compound, will be featured at ASCO. Abstracts include the following: Pooled Safety Analysis of Oblimersen Alone or with Fludarabine and Cyclophosphamide in Patients with Advanced Chronic Lymphocytic Leukemia. Saturday, June 3, 2006, 8:00 am-12:00 pm; Impact of Prognostic Markers on Outcomes in Patients with Advanced Chronic Lymphocytic Leukemia Treated with the Regimen of Fludarabine/Rituximab plus Oblimersen (Bcl-2 Antisense). Saturday, June 3, 2006, 8:00 am-12:00 pm.
GlaxoSmithkline (GSK-NYSE/ADR): will present data on Lapatinib as a first line defense for breast cancer, which has shown to be 35% effective in past reports. Presentation Saturday, June 3, 2006 at 9:30 AM - 10:15 AM.
Hana Biosciences (HNAB-NASDAQ): announced that Phase I trials in solid tumors and non small cell lung cancer with Talotrexin (PT-523) will be presented at ASCO. Details on the presentations are as follows: "A Phase I Study of Talotrexin (PT-523) in Patients with Relapsed or Refractory Non-Small Cell Lung Cancer." on Sunday, June 4th from 8:00am-12:00pm; "Pharmacokinetics of PT-523, A Novel Aminopterin Analogue, in Patients with Solid Tumors." Sunday, June 4th from 2:00-6:00pm.
Introgen (INGN-NASDAQ): will announce important new clinical data for ADVEXIN Cancer Therapy. During presentations at the ASGT on 5/31/06 and at an ASCO-sanctioned symposium, Introgen and its clinical collaborators will discuss clinical trial results and findings related to a set of prognostic indicators associated with high response rates and increased survival of ADVEXIN patients with recurrent squamous cell carcinoma of the head and neck. Also to be presented are the results of a Phase 1 trial, conducted in Japan, of ADVEXIN in patients with advanced non-small cell cancer. In addition to ADVEXIN data, results from studies involving INGN 241 (mda-7/IL24 therapy) and INGN 007 viral cancer therapy programs will be presented.
Millennium Pharmaceuticals, Inc. (MLNM-NASDAQ): announced that additional data from studies of VELCADE will be featured in multiple sessions for multiple indications at ASCO for multiple myeloma, tandem transplants, non-Hodgkins lymphoma, autologous stem cell transplant.
Myriad Genetic (MYGN-NASDAQ): presents "BRCA1/2" mutation prevalence data will be presented on a preliminary basis that has not been verified. FRI JUN 2: 300-515P.
OSI Pharma (OSIP-NASDAQ): Phase 2 for OSIP's Tarceva plus DNA's Avastin data will be presented at ASCO, June 2-6. OSIP will be speaking at the Bear Stearns Biotech conference on 5/31.
Pfizer (PFE-NYSE): expected to release data for experimental cancer drug Sutent at ASCO. Onyx Pharma (ONXX-NASDAQ) has had Sutent act as an overhang on it that it has recently launched with Bayer (BAY-NYSE/ADR) in recent trading.
Pharmacyclics (PCYC-NASDAQ): has said it will have multiple presentations and published abstracts regarding Xcytrin® Injection, including an oral presentation of Phase 3 SMART (Study of Neurologic Progression with Motexafin Gadolinium And Radiation Therapy) trial data. The presentations and publications are part of the proceedings at the 2006 American Society of Clinical Oncology Annual Meeting (ASCO). It will hold an investor reception featuring executive management and SMART trial investigators on Saturday, June 3rd, following the lung cancer session, where additional data and new analyses from the Phase 3 SMART trial will be presented. The company also will host a conference call on Monday, June 5th at 9:00 a.m. EDT to discuss the ASCO presentation.
SuperGen (SUPG-NASDAQ) and MGI Pharma (MOGN-NASDAQ): may announce additional data on the first commercial shipment of Dacogen(TM) (decitabine) injection but it was already announced last week that SuperGen has achieved the $20 million commercialization milestone. Additionally, SuperGen will earn a royalty on worldwide net sales starting at 20% and escalating to a maximum of 30%.
RECENT LEGISLATIVE DEVELOPMENTS IN CANCER
Comprehensive Cancer Care Improvement Act of 2006: Last Wednesday, Reps. Lois Capps (D-CA) and Tom Davis (R-VA) introduced HR 5465, the "Comprehensive Cancer Care Improvement Act of 2006," to reform the Medicare system so it more appropriately pays for all of the services needed to provide patients with comprehensive cancer care.
Medicare Early Detection of Cancer Promotion Act of 2006: HR 5437, the "Medicare Early Detection of Cancer Promotion Act of 2006," introduced May 19 by Rep. Clay Shaw (R-FL), would eliminate coinsurance payments for mammograms and colorectal screenings in Medicare. Currently, Medicare provides coverage for breast, cervical, colon and prostate cancer screening tests, for which beneficiaries must provide a 20 percent co-payment.
-Jon C. Ogg
May 30, 2006
This document is protected by international copyright laws. No third party distribution of this document other than a direct link to the article is allowed without express written understanding from either Doug McIntyre or Jon Ogg. The officers of this organization do not have any positions (Long or Short) of any of the company stocks mentioned in this document. Please send an email to info@newscontrast.com regarding inquiries and redistribution policies of this and other proprietary content.
If you wish to subscribe to our FREE E-NEWSLETTER directly to similar reports and for private content regarding IPO's, M&A, and other important investor information please send an email to info@newscontrast.com with the word EMAIL SUBSCRIBE in the subject field. We value privacy and do not share our mailing lists with any outside partners or vendors.
This Friday will be the launch of the largest cancer and oncology event of the year. The American Society of Clinical Oncology (known as "ASCO" and referred to as ASCO hereafter) annual meeting in Atlanta, Georgia begins on Friday, June 2, 2006 and will go through Tuesday, June 6, 2006.
This is a compiled list of public companies that trade on US exchanges only, as we are geared toward the investment community perspective to this event. It is broken down by a full list exhibitors, a list of which of the companies are in each subset to identify stock candidates ahead of media teases, it also shows recent developments in Congress, and it even has a brief explanation of which companies have either confirmed they are presenting data or that have shown up in media or research reports as presenting data.
This is a few days ahead of the event so the list will only grow with many more companies confirming they intend to present embargoed data at the conference. There are some companies that have been noted recently as already having presented data, but this is discussed in each case.
For several years ASCO has been THE launch platform of choice for many biotech and drug companies to issue embargoed trial and test data to the oncology and investment community. The focus this year seems to be more on combination treatments than on new novel treatments, but in all honesty that can change literally in a matter of three seconds after new potential ground breaking data is presented.
You can peruse the ASCO website (link) to determine additional data. Because of the volume of the data ahead this is a partial document and should be considered work in progress due to the fact that it is certain to expand every few hours.
FULL LIST OF ASCO EXHIBITORS:
Under the full list of exhibitors please note that any longer written explanation than the company being a subsidiary means that the company paid extra to be listed as a Featured Exhibitor on the ASCO Annual Meeting site. The featured exhibitors are listed first and each letter of the alphabet has a space in between letters. This is only a list of the public companies, and there are likely other public company subsidiaries that were either overlooked or that were omitted intentionally. Some of the tickers may also have changed or no longer appear because of the ongoing list of mergers that are present in the medical, drug, and biotech fields.
ABAXIS...division of Abraxis Bioscience, Inc. (ABBI-NASDAQ): Developing innovative, next generation cancer therapies. Through research, innovative science, and creative thinking, we are working to redefine the treatment of cancer as we know it. As it became clear to us that nanotechnology (the science of molecular particles, measured in nanometers—billionths of a meter) would intersect with cellular biology, molecular biology, and medicine, we made the bold commitment to make this convergence happen. We have transformed the highly promising concept of protein-bound particle chemotherapeutics into an exciting new patient reality.
ANTIGENICS INC. (AGEN-NASDAQ): developing Oncophage, an autologous cancer vaccine in late-stage development for metastatic melanoma and RCC. The company's oncology portfolio also includes Aroplatin and AG-858.
ABBOTT (ABT-NYSE)
ADHEREX TECHNOLOGIES INC. (ADH-AMEX)
AETERNA ZENTARIS (AEZS-NASDAQ)
ALLOS THERAPEUTICS, INC. (ALTH-NASDAQ)
AMGEN (AMGN-NASDAQ)
ARIAD PHARMACEUTICALS INC. (ARIA-NASDAQ)
ASTRAZENECA (AZN-NYSE/ADR)
AXCAN PHARMA (AXCA-NASDAQ)
BAYER PHARMACEUTICALS CORPORATION (BAY-NYSE/ADR): discover and manufacture innovative products that will improve human and animal health worldwide by diagnosing, preventing and treating disease.
BAXTER DEUTSCHLAND GMBH, part of Baxter Labs (BAX-NYSE)
BERLEX, part of Schering AG (SHR-NYSE/ADR)
BIO-IMAGING TECHNOLOGIES, INC. (BITI-NASDAQ)
BIOGEN IDEC (BIIB-NASDAQ)
BRISTOL-MYERS SQUIBB (BMY-NYSE)
BSD MEDICAL (BSM-AMEX)
CELGENE CORPORATION (CELG-NASDAQ): innovative therapies enable providers to offer the highest-quality care for better health care outcomes, creating less demand on health care resources.
CELL GENESYS, INC. (CEGE-NASDAQ)
CEPHALON ONCOLOGY (CEPH-NASDAQ)
CEPHEID (CPHD-NASDAQ)
CHARLES RIVER LABORATORIES (CRL-NYSE)
CHIRON, now under Novartis (NVS-NYSE/ADR)
CIPHERGEN (CIPH-NASDAQ)
CLARIENT (CLRT-NASDAQ)
COVANCE (CVD-NYSE)
CYTOGEN CORPORATION (CYTO-NASDAQ)
CYTOKINETICS (CYTK-NASDAQ)
DAKO (majority shareholder is Novo Nordisk (NVO-NYSE/ADR)...pre-IPO intends to list as public stock company: Dako’s primary business area, cell-based cancer diagnostics, is divided into Pathology and Flow Cytometry, which account for 73% and 17% of sales respectively. Added to this is 10% from other products. Dako has a global market share of 35-40% in specific tissue-based cancer tests. Dako has a market share of less than 5% in the world market for flow cytometry.
ELI LILLY & COMPANY (LLY-NYSE): In addition to delivering meaningful support programs, Lilly Oncology has a long-term commitment to advance the treatment of cancer by delivering solutions through innovative technology.
EXELIXIS INCORPORATED (EXEL-NASDAQ): Committed to making a meaningful impact on the lives of cancer patients through the development of first-in or best-in class therapies.
ENZON PHARMACEUTICALS (ENZN-NASDAQ)
FRESENIUS BIOTECH GMBH (FMS-NYSE/ADR)
GE HEALTHCARE, part of General Electric (GE-NYSE): provides transformational medical technologies to help shape a new age of patient care, enabling healthcare providers to better diagnose, treat and manage disease.
GENOMIC HEALTH, INC. (GHDX-NASDAQ): Genomic Health develops clinically validated molecular diagnostics to provide individualized information on the likelihood of disease recurrence and response to therapy for cancer patients.
GENZYME (GENZ-NASDAQ): Leading biotechs dedicated to making a major positive impact on the lives of people with serious diseases.
GENENTECH BIOONCOLOGY, Genentech (DNA-NYSE)
GENITOPE CORPORATION (GTOP-NASDAQ)
GENTA INCORPORATED (GNTA-NASDAQ)
GLAXOSMITHKLINE (GSK-NYSE/ADR)
GTX INC. (GTXI-NASDAQ)
HANA BIOSCIENCES, INC. (HNAB-NASDAQ)
IMCLONE SYSTEMS INC. (IMCL-NASDAQ): dedicated to developing breakthrough medicines in the area of oncology.
IMMUNOMEDICS, INC. (IMMU-NASDAQ): Humanized antibodies tested alone or combined with the radioisotope Yttrium-90; Anti-CD22 Epratuzumab, Anti-CD20 treat NHL and SLE; hPAM4 targets MUC1 expressing pancreatic tumors.
IMS HEALTH (RX-NYSE)
INTROGEN THERAPEUTICS (INGN-NASDAQ)
KENDLE INTERNATIONAL (KNDL-NASDAQ)
KERYX BIOPHARMACEUTICALS, INC. (KERX-NASDAQ)
KYPHON INC. (KYPH-NASDAQ)
MDS PHARMA SERVICES, part of MDS (MDZ-NYSE): manages oncology trials by utilizing renowned experts, advanced technologies, global infrastructure, exceptional drug development strategies and complete clinical capabilities.
MEDIMMUNE ONCOLOGY, INC. (MEDI-NASDAQ) focused infectious diseases, cancer, and inflammatory diseases. The company has four marketed products, including Ethyol® (amifostine).
MGI PHARMA, INC. (MOGN-NASDAQ) markets Aloxi® (palonosetron hydrochloride) Injection and Gliadel® (polifeprosan 20 with carmustine implant) Wafer in the U.S.
MERCK ONCOLOGY (MRK-NYSE)
MILLENNIUM BIOTECHNOLOGIES (MBTG-NASDAQ/OTC)
MILLENNIUM PHARMACEUTICALS INC. (MLNM-NASDAQ)
MYRIAD GENETICS (MYGN-NASDAQ)
NEOPHARM INC. (NEOL-NASDAQ)
NEORX CORPORATION (NERX-NASDAQ)
NOVACEA, INC. (NOVC-NASDAQ) (very recent IPO 5/10/06)
NOVARTIS ONCOLOGY, part of Novartis (NVS-NASDAQ/ADR)
ORTHO BIOTECH PRODUCTS LP, a unit of Johnson & Johnson (JNJ-NYSE): markets PROCRIT(R) (Epoetin alfa) used to treat anemia associated with serious medical conditions.
ONYX PHARMACEUTICALS (ONXX-NASDAQ)
OSI PHARMACEUTICALS (OSIP-NASDAQ)
OXIGENE, INC. (OXGN-NASDAQ)
PHARMANET, a merged company of SFBC (SFCC-NASDAQ)
PRA INTERNATIONAL (PRAI-NASDAQ): a clinical research organization in oncology and special expertise in CNS, respiratory and cardiovascular diseases.
PAREXEL INTERNATIONAL (PRXL-NASDAQ)
PDL BIOPHARMA, INC. (PDLI-NASDAQ)
PFIZER ONCOLOGY, part of Pfizer (PFE-NYSE)
PHARMACYCLICS (PCYC-NASDAQ)
PHARMION CORPORATION (PHRM-NASDAQ)
POINT THERAPEUTICS (POTP-NASDAQ)
PPD (PPDI-NASDAQ)
QUEST DIAGNOSTICS (DGX-NYSE)
ROCHE (RHHBY-NASDAQ/ADR/OTC): Diagnostics and drug development and commercialization in oncology and multiple other disease treatments.
SUPERGEN (SUPG-NASDAQ) dedicated to acquiring, developing, and commercializing therapies for hematologists and oncologists. We market Nipent® (pentostatin for injection), Mitomycin, and SurfaceSafe®.
SANOFI-AVENTIS (SNY-NYSE/ADR)
SAVIENT PHARMACEUTICALS, INC. (SVNT-NASDAQ)
SCHERING-PLOUGH (SGP-NYSE)
SCICLONE PHARMACEUTICALS (SCLN-NASDAQ)
SGX PHARMACEUTICALS, INC. (SGXP-NASDAQ)
SIRTEX MEDICAL, INC. (SXMDF-NASDAQ/ADR/OTC)
TELIK, INC. (TELK-NASDAQ)
THRESHOLD PHARMACEUTICALS (THLD-NASDAQ)
TRANSGENOMIC, INC. (TBIO-NASDAQ)
US ONCOLOGY (former USON-NASDAQ)
VARIAN MEDICAL SYSTEMS (VAR-NYSE): supplier of advanced medical technology and oncology information systems for the treatment of cancer and/or neurological conditions.
VALLEYLAB/TYCO HEALTHCARE, part of Tyco (TYC-NYSE)
VENTANA MEDICAL SYSTEMS (VMSI-NASDAQ)
WATSON PHARMA, INC. (WPI-NYSE)
WYETH (WYE-NYSE)
YM BIOSCIENCES, INC. (YMI-AMEX)
LISTED CATEGORIES OF EACH COMPANY PRESENTATION AT ASCO
This list is from the ASCO website and it seems very incomplete, so these should just be considered incomplete.
Antibodies:
Dako, PDL
Biomarkers:
Genomic Health, Ciphergen , Quest, Transgenomic
Biotechnology (broad-based):
Antigenics, Celgene, Exelixis, Imclone, Medimmune, MGI Pharma, PRA Int'l, Adherex, AEterna Zentaris, ARIAD, Biogen-Idec, Cell Genesys, Genta, Hana Bio, Introgen, Keryx Bio, NeoRX, Novacea, OSI Pharma, Threshold Pharma
Breast Cancer:
Dako, Genomic Health, Roche, BSD Medical, Clarient, GTX, Myriad, Pfizer, Sanofi Aventis, Schering Plough
Cancer Prevention:
GTX Inc.
Cancer Survivorship:
Ciphergen
Clinical Lab Services:
Genomic Health, Genzyme, Biomedical Systems, Clarient, Transgenomic
Clinical Research:
MDS Pharma, PRA Int'l, Charles River, PPD, Threshold
Consulting:
Bio-Imaging
Contract Research:
Charles River, Covance
Cytotoxic Chemotherapy:
AEterna Zentaris, NeoRx, Sanofi Aventis
Diagnostic Imaging and Imaging Services:
GE, Bio-Imaging, Clarient
Gastrointestinal Cancer:
Dako, Immunomedics, Roche, Myriad, Pfizer, Sanofi Aventis, Sirtex, Threshold
Genitourinary Cancer:
Cell Genesys, GTX, Novacea, Onyx Pharma
Gynecological Cancer:
AEterna Zentaris, Ciphergen, Schering Plough
Head & Neck Cancer:
Medimmune, Introgen
Health Services Research:
IMS Health
Hematologic Cancer:
Celegene, Biogen Idec, Cephalon, Enzon, Novartis, Pharmion
Human Genetics:
Myriad
Immunotherapy:
Antigenics, Biogen Idec, Cell Genesys, Schering Plough
Lab Services:
Genzyme, MDS Pharma, Covance, Quest, Transgenomic
Leukemia/Lymphoma:
Celgene, Immunomedics, SuperGen, Allos, Cephalon, Enzon, Genta, PDL, Pharmacyclics, Point Therapeutics
Lung Cancer:
Axcan, NeoRx, PDL, Pharmacyclics, Point Therapeutics
Medical Devices:
Abaxis, BSD Medical, Kyphon, Valleylab/Tyco
Medical Equipment:
GE, Varian, Abaxis
Melanoma:
Antigenics, Genta, Point Therapeutics
Metastatic Disease or Brain Metastases:
Allos, Phamrcyclics, Sirtex
Microarray:
Quest
Molecular Therapeutics:
Exelixis, Onyx Pharma, OSI Pharma
Nuclear Medicine:
Immunomedics, Sirtex
Nutritional Support:
Millennium Biotechnologies-MBTG, Savient
Pediatric Oncology:
Genzyme, Enzon
Pharmaceutical (broad-based):
Bayer, Eli Lilly, Exelixis, MGI Pharma, Ortho-JNJ, Supergen, Allos, Axcan, Bristol-Myers Squibb, GlaxoSmithkline, Keryx, Millennium Pharmaceuticals-MLNM, Novacea, Novartis, OSI Pharma, Pfizer, Pharmion, Sciclone, Solvay, Wyeth
Research Technology:
SuperGen
Supportive Care:
MGI Pharma, Roche, Cephalon, Hana Bio, Savient
Trial Management:
MDS Pharma, PRA Int'l, Varian, Charles River, Covance, PPD
COMPANIES WITH NEWS OR PRESENTATIONS EXPECTED OR ANNOUNCED AT ASCO AHEAD OF TIME:
ABAXIS, a division of Abraxis Bioscience, Inc. (ABBI-NASDAQ): expected to post nanotech convergence for cancer treatments in the future.
Adherex Technologies (ADH-AMEX): Announced that the Company has concluded the Phase Ib component of its Phase Ib/II ADH-1 trial in Europe and has begun the expanded accrual restricted to lung and ovarian cancers. The study, which is examining a weekly dosing schedule of ADH-1, will now enroll patients at the maximum studied dose of 2400 mg/m2 with N-cadherin positive non-small cell lung cancer and ovarian cancer. The Company expects to enroll approximately 20 further patients in this trial. The number of patients enrolled could be increased, depending on the level of anti-tumor activity noted. The Phase Ib data will be reported at a poster discussion presentation at the 2006 American Society of Clinical Oncology Annual meeting on Saturday, June 3, 2006 from 8 a.m.-1 p.m.
Amgen (AMGN-NASDAQ): Set to report on Denosumab, an experimental osteoporosis treatment formerly known as AMG-162, could receive accelerated approval should pending Phase II data prove positive. Phase II trials to be presented at ASCO; not confirmed since this is indicated as osteoporosis treatment but it is indicated for metastatic bone diseases.
ARIAD (ARIA-NASDAQ): Comprehensive Clinical Data on ARIAD's Novel mTOR Inhibitor, AP23573, to Be Presented at the ASCO Annual Meeting. ARIAD to Host Investor Conference Call on June 5, 2006 at 6:30 p.m. EST.
BSD Medical (BSM-AMEX): may Re-report progress in the application of hyperthermia therapy to the treatment of soft tissue sarcomas, breast cancer, ovarian cancer, cervical cancer, prostate cancer, bladder cancer, esophagus cancer, gastric cancer, pancreatic cancer, intra-peritoneal cancer and colorectal cancer. This data has been presented just last week.
Celgene (CELG-NASDAQ): expected to update Phase II data for Rivlimid in the treatment of chronic lymphocytic leukemia and updates on the Revlimid phase 2 trails in multiple myeloma at ASCO.
Cell Genesys (CEGE-NASDAQ): may re-release reports of Interim Results of CG0070 Phase 1 Trial in Bladder Cancer after 3 of 9 showed a complete response and no one had side effects and the company plans to expand trial enrollment.
Exelixis (EXEL-NASDAQ): was notified by participating clinical investigators that abstracts containing data from the company's Phase I clinical trials of XL647, XL880 and XL999 have been accepted for ASCO. Data from the Phase I trials of XL647 and XL880 will be presented and discussed in the Developmental Therapeutics: Molecular Therapeutics session at 12:00 p.m. ET on Saturday, June 3rd and data from the weekly dosing arm of the Phase I XL999 trial will be published in abstract form.
Genetech (DNA-NYSE): Phase II for OSIP's Tarceva plus DNA's Avastin data will be presented. Genentech-DNA has recently received an indication for Avastin in metastatic breast cancer according to reports.
Genomic Health (GHDX-NASDAQ): reportedly will be presenting beneficial data of its Oncotype DX that will be used in a large scale study that was just initiated by the National Cancer Institute in approximately 10,000 patients and 900 centers.
Genta Inc. (GNTA-NASDAQ): announced that several abstracts related to Genasense® (oblimersen sodium) Injection, the Company's lead anticancer compound, will be featured at ASCO. Abstracts include the following: Pooled Safety Analysis of Oblimersen Alone or with Fludarabine and Cyclophosphamide in Patients with Advanced Chronic Lymphocytic Leukemia. Saturday, June 3, 2006, 8:00 am-12:00 pm; Impact of Prognostic Markers on Outcomes in Patients with Advanced Chronic Lymphocytic Leukemia Treated with the Regimen of Fludarabine/Rituximab plus Oblimersen (Bcl-2 Antisense). Saturday, June 3, 2006, 8:00 am-12:00 pm.
GlaxoSmithkline (GSK-NYSE/ADR): will present data on Lapatinib as a first line defense for breast cancer, which has shown to be 35% effective in past reports. Presentation Saturday, June 3, 2006 at 9:30 AM - 10:15 AM.
Hana Biosciences (HNAB-NASDAQ): announced that Phase I trials in solid tumors and non small cell lung cancer with Talotrexin (PT-523) will be presented at ASCO. Details on the presentations are as follows: "A Phase I Study of Talotrexin (PT-523) in Patients with Relapsed or Refractory Non-Small Cell Lung Cancer." on Sunday, June 4th from 8:00am-12:00pm; "Pharmacokinetics of PT-523, A Novel Aminopterin Analogue, in Patients with Solid Tumors." Sunday, June 4th from 2:00-6:00pm.
Introgen (INGN-NASDAQ): will announce important new clinical data for ADVEXIN Cancer Therapy. During presentations at the ASGT on 5/31/06 and at an ASCO-sanctioned symposium, Introgen and its clinical collaborators will discuss clinical trial results and findings related to a set of prognostic indicators associated with high response rates and increased survival of ADVEXIN patients with recurrent squamous cell carcinoma of the head and neck. Also to be presented are the results of a Phase 1 trial, conducted in Japan, of ADVEXIN in patients with advanced non-small cell cancer. In addition to ADVEXIN data, results from studies involving INGN 241 (mda-7/IL24 therapy) and INGN 007 viral cancer therapy programs will be presented.
Millennium Pharmaceuticals, Inc. (MLNM-NASDAQ): announced that additional data from studies of VELCADE will be featured in multiple sessions for multiple indications at ASCO for multiple myeloma, tandem transplants, non-Hodgkins lymphoma, autologous stem cell transplant.
Myriad Genetic (MYGN-NASDAQ): presents "BRCA1/2" mutation prevalence data will be presented on a preliminary basis that has not been verified. FRI JUN 2: 300-515P.
OSI Pharma (OSIP-NASDAQ): Phase 2 for OSIP's Tarceva plus DNA's Avastin data will be presented at ASCO, June 2-6. OSIP will be speaking at the Bear Stearns Biotech conference on 5/31.
Pfizer (PFE-NYSE): expected to release data for experimental cancer drug Sutent at ASCO. Onyx Pharma (ONXX-NASDAQ) has had Sutent act as an overhang on it that it has recently launched with Bayer (BAY-NYSE/ADR) in recent trading.
Pharmacyclics (PCYC-NASDAQ): has said it will have multiple presentations and published abstracts regarding Xcytrin® Injection, including an oral presentation of Phase 3 SMART (Study of Neurologic Progression with Motexafin Gadolinium And Radiation Therapy) trial data. The presentations and publications are part of the proceedings at the 2006 American Society of Clinical Oncology Annual Meeting (ASCO). It will hold an investor reception featuring executive management and SMART trial investigators on Saturday, June 3rd, following the lung cancer session, where additional data and new analyses from the Phase 3 SMART trial will be presented. The company also will host a conference call on Monday, June 5th at 9:00 a.m. EDT to discuss the ASCO presentation.
SuperGen (SUPG-NASDAQ) and MGI Pharma (MOGN-NASDAQ): may announce additional data on the first commercial shipment of Dacogen(TM) (decitabine) injection but it was already announced last week that SuperGen has achieved the $20 million commercialization milestone. Additionally, SuperGen will earn a royalty on worldwide net sales starting at 20% and escalating to a maximum of 30%.
RECENT LEGISLATIVE DEVELOPMENTS IN CANCER
Comprehensive Cancer Care Improvement Act of 2006: Last Wednesday, Reps. Lois Capps (D-CA) and Tom Davis (R-VA) introduced HR 5465, the "Comprehensive Cancer Care Improvement Act of 2006," to reform the Medicare system so it more appropriately pays for all of the services needed to provide patients with comprehensive cancer care.
Medicare Early Detection of Cancer Promotion Act of 2006: HR 5437, the "Medicare Early Detection of Cancer Promotion Act of 2006," introduced May 19 by Rep. Clay Shaw (R-FL), would eliminate coinsurance payments for mammograms and colorectal screenings in Medicare. Currently, Medicare provides coverage for breast, cervical, colon and prostate cancer screening tests, for which beneficiaries must provide a 20 percent co-payment.
-Jon C. Ogg
May 30, 2006
This document is protected by international copyright laws. No third party distribution of this document other than a direct link to the article is allowed without express written understanding from either Doug McIntyre or Jon Ogg. The officers of this organization do not have any positions (Long or Short) of any of the company stocks mentioned in this document. Please send an email to info@newscontrast.com regarding inquiries and redistribution policies of this and other proprietary content.
If you wish to subscribe to our FREE E-NEWSLETTER directly to similar reports and for private content regarding IPO's, M&A, and other important investor information please send an email to info@newscontrast.com with the word EMAIL SUBSCRIBE in the subject field. We value privacy and do not share our mailing lists with any outside partners or vendors.
posted by Jon C. Ogg at 11:40 AM
Subscribe
<< Home